



FOR IMMEDIATE RELEASE

Vital Therapies Completes First Closing of \$8 Million Private Equity Financing

Financing will fund pivotal clinical trials

San Diego, November 1, 2005 – Vital Therapies, Inc. (VTI) announced today that it has completed the first close of the Company's Se

Further information on MedVenture Associates can be found at www.medven.com, Toucan Capital at www.toucancapital.com and Valley Ventures at www.valleyventures.com.

About Liver Disease

The World Health Organization (WHO) defines the worldwide market for acute-on-chronic liver failure as approximately 12 million patients. Currently, the only widely accepted therapy for liver failure is transplantation. In the United States, liver disease is the 12th overall cause of death and the 7th leading cause in the 25-44 and 45-64 year-old